Generic Cuvrior Availability
Last updated on Aug 7, 2024.
Cuvrior is a brand name of trientine, approved by the FDA in the following formulation(s):
CUVRIOR (trientine tetrahydrochloride - tablet;oral)
-
Manufacturer: ORPHALAN
Approval date: April 28, 2022
Strength(s): 300MG [RLD]
Has a generic version of Cuvrior been approved?
No. There is currently no therapeutically equivalent version of Cuvrior available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cuvrior. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 10,988,436
Patent expiration dates:
- May 3, 2039✓
- May 3, 2039
-
Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
Patent 11,072,577
Issued: July 27, 2021
Inventor(s): Morley Timothy James & Lawrence Ronnie Maxwell & Amin Naseem
Assignee(s): Orphalan S.A.The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2θ and Raman shifts 943, 1173, 1527 and 1612±5 cm. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
Patent expiration dates:
- May 3, 2039✓
- May 3, 2039
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- April 28, 2025 - NEW PRODUCT
- April 28, 2029 - TREATMENT OF ADULT PATIENTS WITH STABLE WILSON’S DISEASE WHO ARE DE-COPPERED AND TOLERANT TO PENICILLAMINE
More about Cuvrior (trientine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: chelating agents
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.